Cargando…

The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran

INTRODUCTION: The decision to start insulin therapy is often difficult. Determining the barriers against insulin therapy initiation can facilitate care and treatment strategies. The aim of this study was to evaluate the barriers against initiating insulin therapy among patients with diabetes living...

Descripción completa

Detalles Bibliográficos
Autores principales: Shafie Pour, MR, Sadeghiyeh, T, Hadavi, M, Besharati, M, Bidaki, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689560/
https://www.ncbi.nlm.nih.gov/pubmed/31496772
http://dx.doi.org/10.2147/DMSO.S200867
_version_ 1783443043624419328
author Shafie Pour, MR
Sadeghiyeh, T
Hadavi, M
Besharati, M
Bidaki, R
author_facet Shafie Pour, MR
Sadeghiyeh, T
Hadavi, M
Besharati, M
Bidaki, R
author_sort Shafie Pour, MR
collection PubMed
description INTRODUCTION: The decision to start insulin therapy is often difficult. Determining the barriers against insulin therapy initiation can facilitate care and treatment strategies. The aim of this study was to evaluate the barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran. METHODS: This descriptive study was conducted on 214 patients referred to the Diabetes Center of Yazd University of Medical Sciences in 2015. Participants were randomly selected, and then they completed the insulin noncompliance questionnaire (20 questions). The percentage of adherence and the factors contributing to nonadherence to insulin therapy were analyzed using descriptive statistics, the Kruskal–Wallis test, and the Mann–Whitney test. RESULTS: The most prevalent reason for insulin therapy refusal was expecting a new method of diabetes treatment (54.7%), followed by requiring someone else to administer the injection (19.2%), fear of needles, cost, traveling (18.7%), and stress/emotional problems (18.2%). Lack of trust in the physician was the least restrictive reason for nonadherence to insulin therapy. CONCLUSION: The most common reason given for insulin therapy refusal was the lack of adequate education. Therefore, specialized educational interventions can help minimize barriers and improve patients’ outcomes.
format Online
Article
Text
id pubmed-6689560
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66895602019-09-06 The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran Shafie Pour, MR Sadeghiyeh, T Hadavi, M Besharati, M Bidaki, R Diabetes Metab Syndr Obes Original Research INTRODUCTION: The decision to start insulin therapy is often difficult. Determining the barriers against insulin therapy initiation can facilitate care and treatment strategies. The aim of this study was to evaluate the barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran. METHODS: This descriptive study was conducted on 214 patients referred to the Diabetes Center of Yazd University of Medical Sciences in 2015. Participants were randomly selected, and then they completed the insulin noncompliance questionnaire (20 questions). The percentage of adherence and the factors contributing to nonadherence to insulin therapy were analyzed using descriptive statistics, the Kruskal–Wallis test, and the Mann–Whitney test. RESULTS: The most prevalent reason for insulin therapy refusal was expecting a new method of diabetes treatment (54.7%), followed by requiring someone else to administer the injection (19.2%), fear of needles, cost, traveling (18.7%), and stress/emotional problems (18.2%). Lack of trust in the physician was the least restrictive reason for nonadherence to insulin therapy. CONCLUSION: The most common reason given for insulin therapy refusal was the lack of adequate education. Therefore, specialized educational interventions can help minimize barriers and improve patients’ outcomes. Dove 2019-08-07 /pmc/articles/PMC6689560/ /pubmed/31496772 http://dx.doi.org/10.2147/DMSO.S200867 Text en © 2019 Shafie Pour et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Shafie Pour, MR
Sadeghiyeh, T
Hadavi, M
Besharati, M
Bidaki, R
The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran
title The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran
title_full The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran
title_fullStr The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran
title_full_unstemmed The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran
title_short The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran
title_sort barriers against initiating insulin therapy among patients with diabetes living in yazd, iran
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689560/
https://www.ncbi.nlm.nih.gov/pubmed/31496772
http://dx.doi.org/10.2147/DMSO.S200867
work_keys_str_mv AT shafiepourmr thebarriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran
AT sadeghiyeht thebarriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran
AT hadavim thebarriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran
AT besharatim thebarriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran
AT bidakir thebarriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran
AT shafiepourmr barriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran
AT sadeghiyeht barriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran
AT hadavim barriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran
AT besharatim barriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran
AT bidakir barriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran